Pathogenetic Aspects of Preventive Correction of Cognitive Impairment in Metabolic Syndrome

T.I. Nasonova


Objective. To study the opportunities to increase the efficiency of pathogenetic therapy in patients with chronic cerebrovascular diseases (CVD) (discirculatory encephalopathy, DE) on the background of metabolic syndrome (MS) using the drug Vitaxon®. The feature of the work was to identify strategic areas of the brain in cognitive and emotional disorders in patients with MS and its absence. Materials and methods. We observed 49 patients with DE II degree aged 37 to 73 years against the background of MS. The main group — 30 patients — received Vitaxon® as a part of treatment. The control group consisted of 19 patients with DE degree II following MS, comparable in the age and stage of the disease, who were not taking Vitaxon®. Patients were observed for 12 weeks. In addition to neurological, general clinical examinations, detection of MS signs, we have used neuropsychological tests by Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (МоСА), Spielberger anxiety scale; Beck depression scale; study of attention: search of numbers by Schulte tables with the assessment of task-performance time. The brain and its liquor system in 41 patients (27 patients with MS — the first group and 14 patients without MS — the second group) were evaluated using the method of volumetry (measuring the volume of certain brain regions), on the magnetic resonance imaging scanner Toshiba Vantage Titan 1.5. Results. Cognitive impairment in both groups manifested by the loss of memory, attention disorders, slowing of mental processes. After 12 weeks, the median by the MMSE significantly increased by 3.3 % (p < 0.05 compared with the first test) in patients who received Vitaxon®. By МоСА, which is more sensitive when determining the mild cognitive impairment, in a group of Vitaxon® cognitive functions improved by 5 %, while in the control group — by 1.66 %. By Spielberger scale, state anxiety indicators improved more in the group of patients who received study drug: at baseline — 42.4 ± 3.4 points and 24.6 ± 2.8 points at week 12 (p < 0.05). It was determined that cognitive performance by МоСА scale was inversely dependent on the parameters of glycated hemoglobin. Results of volumetric studies showed significant (p < 0.05) reduction in the volume of the brain substance, cortex and the volume of white matter of the cerebral hemispheres, temporal lobe in patients with CVD on the background of MS compared with those of similar age with no signs of MS. In addition, patients with MS had the likely decrease in the area of the corpus callosum (p < 0.05) compared to patients without MS. Conclusions. During the treatment of patients with CVD following MS, it is necessary to consider anxiety-asthenic conditions and cognitive disorders that often occur at this pathology. Addition of Vitaxon® to the generally accepted drug therapy helps to eliminate psycho-emotional disorders. In patients with chronic CVD on the background of MS, the degree of the atrophy of the cortex and white matter of the cerebral hemispheres, the frontal and temporal lobes, as well as the corpus callosum, was significantly higher (p < 0.05) compared to patients without MS.


metabolic syndrome; discirculatory encephalopathy; treatment; Vitaxon®.


Zaharov V.V. Lechenie kognitivnyih narusheniy pri distsirkulyatornoy entsefalopatii / Zaharov V.V., Stepkina D.A. // Rossiyskiy meditsinskiy zhurnal. – 2015. – #1. – S.953-956.

Damulin I.V. Bolezn Altsgeymera i sosudistaya dementsiya / Pod red. N.N.Yahno // M., 2002. – S.85.

Damulin I.V. Narusheniya krovoobrascheniya v golovnom i spinnom mozge / Damulin I.V., Parfenov V.A., Skoromets A.A., Yahno N.N.// Bolezni nervnoy sistemyi: rukovodstvo dlya vrachey / Pod redaktsiey N.N.Yahno, D.R.Schtulmana. – M., 2005. – S.231-302.

Varakin Yu.Ya. Osobennosti vyiyavleniya patsientov s nachalnyimi proyavleniyami hronicheskoy tserebrovaskulyarnoy patologiey pri obsledovanii naseleniya./ Varakin Yu.Ya., Gornostaeva G.V., Kravchenko M.A. // Materialyi 14-y Mezhdunarodnoy konferentsii «Vozrastnyie aspektyi nevrologii» – 2012. – S.2-5.

Kuduhova A.V. Ishemicheskie tserebrovaskulyarnyie zabolevaniya na fone metabolicheskogo sindroma: sostoyanie serdechno-sosudistoy sistemyi./ A.V. Kuduhova // M., 2012. – 160 s.

Telenkova N.G. Gematovazalnyie vzaimodeystviya pri hronicheskih tserebrovaskulyarnyih zabolevaniyah na fone metabolicheskogo sindroma./ Dissertatsiya na soiskanie uchenoy stepeni kandidata meditsinskih nauk. – M., 2010. – 24 s.

Luchinger JA, Tang MX et al. Hyperinsulinemia and risk of Alzheimier disease. Neurology 2004; 63: 1187-1192.

Hassing LB, Grant MD, Hofer SM et al. Type 2 diabetes mellitus contributes to cognitive decline in old age: a longitudinal population-based study. J Int Neuropsychol Soc. 2004; 10: 599-607.

Komulainen P, Lakka TA, Kivipelto M et al. Metabolic syndrome and cognitive function: a population-based follow-up study in elderly women. Dement Geriatr Cogn Disord. 2007; 23: 29-34.

Esin R.G. Sovremennyie predstavleniya o mehanizmah kognitivnyih rasstroystv pri saharnom diabete./ R.G.Esin, I.H. Hayrullin, O.R. Esin // Meditsinskiy almanah. – 2013-.#1 (25) -S.135-138.

Convit A, Wolf OT, Tarshish C, de Leon MJ. Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proc Natl Acad Sci USA 2003; 2019-2022.

Hassing LB, Hofer SM, Nilsson SE et al. Comorbid type 2 diabetes mellitus and hypertension exacerbates cognitive decline: evidence from a longitudinal study. Age and Ageing. 2004; 33: 355-61.

Posner HB, Tang M-X, Luchsinger J. The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology. 2002;58: 1175-81.

Peila R, Rodriguez BL, Launer LJ. Honolulu-Asia Aging Study Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies. Diabetes. 2002;51: 1256-62.

Brummett BH, Austin SB, Welsh-Bohmer KA, Williams RB, Siegler IC. Long-Term Impact of Caregiving and Metabolic Syndrome with Perceived Decline in Cognitive Function 8 Years Later: A Pilot Study Suggesting Important Avenues for Future Research. Open Journal of Medical Psychology 2013; 2:23-8.

Holin A.V. Magnitno-rezonansnaya tomografiya pri zabolevaniyah tsentralnoy nervnoy sistemyi. / Holin A.V. rukovodstvo dlya vrachey. // Sankt-Peterburg. Izdatelstvo «Gippokrat» -2000. - S 69.

Kopchak O.O. KognItivnI ta neyrovIzualIzatsIynI harakteristiki (za danimi MRT) u hvorih Iz distsirkulyatornoyu entsefalopatIEyu ta metabolIchnim sindromom. / Kopchak O.O. // Mezhdunarodnyiy nevrologicheskiy zhurnal #8 (54) 2012.

Shishkova V. Kognitivnyiy defitsit u patsientov s metabolicheskim sindromom /Shishkova V., Osyichenko M. // Vrach. 2012. # 3. S. 30.

Roosendaal SD, Geurts JJ, Vrenken H еt al. Regional DTI differences in multiple sclerosis patients. Neuroimage. 2009; 44(4): 1397-403.

Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurology. 2004; 3: 169-78.

Zimmer P, Shaw G, Alberti G. Preventing type 2 diabetes and the dysmetabolic syndrome in the real word: a realistic view. Deabetic medicine. 2003; 20 (9): 693-702.

Valdés-Ramos R, Guadarrama-López AL, Martínez-Carrillo BE, Benítez-Arciniega AD. Vitamins and type 2 diabetes mellitus. Endocr Metab Immune Disord Drug Targets. 2015;15(1):54-63.

de Jager J, Kooy A, Lehert P, Wulffelé MG, van der Kolk J, Bets D, Verburg J, Donker AJ, Stehouwer CD. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ. 2010; 20;340: 2181. doi: 10.1136/bmj.c2181

Nasonova T.I. KorektsIya klInIko-metabolIchnih porushen u hvorih z tserebrovaskulyarnimi zahvoryuvannyami na fonI metabolIchnogo sindromu. EndokrinologIya. 2015;20,#4:S.677-685.



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© "Publishing House "Zaslavsky", 1997-2017


 Яндекс.МетрикаSeo анализ сайта Рейтинг